Dominique Stump
Telomere diagnostics firm Life Length has received an estimated $3.5 million grant from the European Union under the Horizon 2020 program to support the company’s clinical studies on a potential biomarker for cancer treatment.
The Telomere Analysis Technology cellular health biomarker works to identify the biological health of cells, measure the effects of lifestyle programs and detect the risk and early onset of cardiovascular and metabolic diseases and cancer, the company said Thursday.
Life Length added it will partner with hospitals in Spain over the next two years for the ONCOCHECK project, which will involve approximately 1,500 cancer patients.
The grant comes as the company secured ISO 15189 accreditation for quality diagnostics testing, Platinum accreditation by the American Association for Laboratory Accreditation and certification as a clinical and diagnostic laboratory by the Center for Medicare and Medicaid Services.
